Table 3.
Myeloid-specific ikkβ gene deletion ameliorates transferred EAE
| Group | Incidence (%) | Mean day of onset (± SEM) | Maximal clinical score (± SEM) | Sun of clinical score (± SEM) | Mortality (%) |
|---|---|---|---|---|---|
| Wild type | 5/5 | 7.4 ± 1.6 | 4.2 ± 0.7 | 43.7 ± 10.6 | 10 |
| →Wild type | |||||
| Wild type | 5/5 | 9.4 ± 0.2 | 3.6 ± 0.2 | 33.7 ± 2.1 | 0 |
| →LysM-Cre/Ikkβ F/F | |||||
| LysM-Cre/Ikkβ F/F | 5/5 | 13.6 ± 1.6* | 0.7 ± 0.1** | 7.5 ± 2.1** | 0 |
| →Wild type | |||||
| LysM-Cre/Ikkβ F/F | 5/5 | 11.6 ± 1.4 | 1.4 ± 0.2** | 12.9 ± 1.8** | 0 |
| →LysM-Cre/Ikkβ F/F |
T cells were isolated from lymph nodes of WT or LysM-Cre/Ikkβ F/F donor 15–18 days after induction of active EAE and re-stimulated with MOG35–55 peptide. Purified T cells (1 × 107) were transferred i.v. into sub-lethally irradiated WT or LysM-Cre/Ikkβ F/F recipient mice. (ANOVA test; *p < 0.05 and **p < 0.01 versus WT → WT group)